Patients within the project and their physicians will be able to access Genome Medical's genetic specialists to address concerns and incorporate genetic information into care.
My Gene Counsel's confirmatory testing program is the latest example of how the healthcare system is adapting to consumers' growing appetite for genetic testing.
Healthcare providers continue to worry about the impact of 23andMe's health risk reports but there is also growing acceptance of the DTC testing model.
The new channel, to be launched in the second quarter, is part of the company's plan to make genetic testing affordable and accessible to everyone.
Direct-to-consumer genetic testing firm 23andMe has a newly cleared colorectal cancer risk test.
LunaDNA parent company LunaPBS will combine its technology platform with Genetic Alliance's PEER system to advance patient-centric research.
In an effort to lift patient access barriers, the company is launching a model whereby consumers will be able to initiate test orders online.
Blockchain-based startup EncrypGen will take advantage of Murrieta Genomics' sequencing lab and business services to market its Gene-Chain platform for data sharing.
As consumer genomics firms ramp up marketing for Alzheimer's risk tests, one support group says experts should help people understand the results and potential negative effects.
Myriad CEO Mark Capone said earnings during the quarter exceeded expectations based on strong volume growth from hereditary cancer and new products.
The long-running Framingham Heart Study has received a $38 million grant, according to the Boston Globe.
A Stanford University investigation finds that its researchers did not take part in He Jiankui's work to develop gene-edited infants.
Retraction Watch reports that two researchers had both a Science and a Nature paper retracted last week.
In Genome Biology this week: genomic sequencing of milkweed bug, benchmark comparison of single-cell RNA sequencing platforms, and more.